UNSPSC 51311704: Phenyltoloxamine citrate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H21NO.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8UE48MJH8M, chemically known as n,n-dimethyl-2-(alpha-phenyl-o-toloxy)ethylamine dihydrogen citrate but more generally known as phenyltoloxamine citrate, which bears US NIH Compound Identifier 14440. European Medicines Agency schedules Phenyltoloxamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03784MIG.

UNSPSC 51311704 Phenyltoloxamine citrate is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent opportunities show the code is being applied to a broader range of pharmaceutical and health-supply procurement than the specific active ingredient name suggests. State and local governments buying under this code are acquiring naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products to support community health initiatives, pharmacy benefit programs, and public-health emergency response. Issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, procures naloxone and drug deactivation systems through competitive bidding to support community health initiatives. The Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, establishes master contracts for generic pharmaceuticals and OTC products distributed across multiple participating state and local government facilities, including Oregon.

Recent activity is concentrated in Florida, Texas, and the upper Midwest. The Seminole County IFB (Solicitation IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS RFI (HHS0017013), posted April 3, 2026, sought vendor capabilities for direct-to-manufacturer prescription programs serving self-insured employers and state agencies. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with a response deadline of March 26, 2026, established master contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and operational capability including EDI functionality and cGMP/DSCSA certification.